-
EP4337649
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4337649
| EP4337649 - SUBSTITUTED HETEROCYCLIC COMPOUNDS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 16.02.2024 Database last updated on 22.05.2024 | |
| Former | The international publication has been made Status updated on 29.11.2022 | ||
| Former | unknown Status updated on 14.06.2022 | Most recent event Tooltip | 13.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US | [2024/12] | Inventor(s) | 01 /
SPERGEL, Steven, H. Princeton, New Jersey 08543 / US | 02 /
MOSLIN, Ryan, M. Princeton, New Jersey 08543 / US | 03 /
MERTZMAN, Michael, Edward Princeton, New Jersey 08543 / US | 04 /
POSY, Shoshana, L. Princeton, New Jersey 08543 / US | 05 /
LAKKARAJU, Sirish, Kaushik Princeton, New Jersey 08543 / US | 06 /
TINO, Joseph, A. Lawrenceville, NJ 08648 / US | 07 /
XIAO, Zili Princeton, New Jersey 08543 / US | 08 /
LIU, Chunjian Princeton, New Jersey 08543 / US | 09 /
LIN, James Lawrenceville, New Jersey 08648 / US | [2024/12] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/12] | Application number, filing date | 22727675.5 | 13.05.2022 | [2024/12] | WO2022US29105 | Priority number, date | US202163188498P | 14.05.2021 Original published format: US 202163188498 P | US202263328835P | 08.04.2022 Original published format: US 202263328835 P | [2024/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022241172 | Date: | 17.11.2022 | Language: | EN | [2022/46] | Type: | A1 Application with search report | No.: | EP4337649 | Date: | 20.03.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.11.2022 takes the place of the publication of the European patent application. | [2024/12] | Search report(s) | International search report - published on: | EP | 17.11.2022 | Classification | IPC: | C07D401/12, C07D401/14, C07D403/12, C07D413/12, C07D417/12, C07D417/14, A61P29/00, A61P37/00, A61K31/501 | [2024/12] | CPC: |
C07D413/12 (EP,KR);
A61K31/501 (KR);
A61P25/16 (KR);
A61P25/28 (KR);
A61P29/00 (EP);
A61P37/00 (EP,KR);
C07D401/12 (EP,KR);
C07D401/14 (EP,KR);
C07D403/12 (EP,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/12] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | SUBSTITUIERTE HETEROCYCLISCHE VERBINDUNGEN | [2024/12] | English: | SUBSTITUTED HETEROCYCLIC COMPOUNDS | [2024/12] | French: | COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS | [2024/12] | Entry into regional phase | 12.12.2023 | National basic fee paid | 12.12.2023 | Designation fee(s) paid | 12.12.2023 | Examination fee paid | Examination procedure | 12.12.2023 | Examination requested [2024/12] | 12.12.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 13.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2014074661 (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-8* examples 120, 149, 160, 162, 192, 194, 196;; examples 54, 63, 64, 70, 72, 75, 82, 86, 95, 101, 105, 116 *; | [Y]WO2020156311 (JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD [CN], et al) [Y] 1-8 * examples 5, 14 * | by applicant | US9505748 | USRE47929E | - MCGEACHY, M.J. et al., "The link between IL-23 and Thl7 cell-mediated immune pathologies", Semin. Immunol., (20070000), vol. 19, doi:10.1016/j.smim.2007.10.012, pages 372 - 376, XP022495318 DOI: http://dx.doi.org/10.1016/j.smim.2007.10.012 | - GRACIE, J.A. et al., "Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass", Eur. J. Immunol., (19960000), vol. 26, pages 1217 - 1221 | - SCHRODER, K. et al., "Interferon-gamma: an overview of signals, mechanisms and functions", J. Leukoc. Biol., (20040000), vol. 75, no. 2, doi:10.1189/jlb.0603252, pages 163 - 189, XP009031305 DOI: http://dx.doi.org/10.1189/jlb.0603252 | - KYTTARIS, V.C. et al., "Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice", J. Immunol., (20100000), vol. 184, pages 4605 - 4609 | - HONG, K. et al., "IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis like skin disorder", J. Immunol., (19990000), vol. 162, pages 7480 - 7491, XP002188301 | - HUE, S. et al., "Interleukin-23 drives innate and T cell-mediated intestinal inflammation", J. Exp. Med., (20060000), vol. 203, doi:10.1084/jem.20061099, pages 2473 - 2483, XP055111922 DOI: http://dx.doi.org/10.1084/jem.20061099 | - CUA, D.J. et al., "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030000), vol. 421, doi:10.1038/nature01355, pages 744 - 748, XP002971969 DOI: http://dx.doi.org/10.1038/nature01355 | - MURPHY, C.A. et al., "Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation", J. Exp. Med., (20030000), vol. 198, pages 1951 - 1957 | - LEE, E. et al., "Increased expression of interleukin 23 pl9 and p40 in lesional skin of patients with psoriasis vulgaris", J. Exp. Med., (20040000), vol. 199, pages 125 - 130 | - TZARTOS, J.S. et al., "Interleukin-17 production in central nervous system infiltrating T cells and glial cells is associated with active disease in multiple sclerosis", Am. J. Pathol., (20080000), vol. 172, pages 146 - 155 | - HUANG, X. et al., "Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients", Mod. Rheumatol., (20070000), vol. 17, pages 220 - 223, XP019495284 | - TUCCI, M. et al., "Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis", Clin. Exp. Immunol., (20080000), vol. 154, doi:10.1111/j.1365-2249.2008.03758.x, pages 247 - 254, XP071084331 DOI: http://dx.doi.org/10.1111/j.1365-2249.2008.03758.x | - LEES, C.W. et al., "New IBD genetics: common pathways with other diseases", Gut, (20110000), vol. 60, pages 1739 - 1753 | - TAO, J.H. et al., "Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases", Mol. Biol. Rep.,, (20110000), vol. 38, doi:10.1007/s11033-010-0601-5, pages 4663 - 4672, XP019945210 DOI: http://dx.doi.org/10.1007/s11033-010-0601-5 | - CHO, J.H. et al., "Recent insights into the genetics of inflammatory bowel disease", Gastroenterology, (20110000), vol. 140, pages 1704 - 1712 | - LEONARDI, C.L. et al., "PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)", Lancet, (20080000), vol. 371, pages 1665 - 1674 | - SANDBORN, W.J. et al., "Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease", Gastroenterology, (20080000), vol. 135, pages 1130 - 1141 | - GOTTLIEB, A. et al., "Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial", Lancet, (20090000), vol. 373, pages 633 - 640 | - HALL, J.C. et al., "Type I interferons: crucial participants in disease amplification in autoimmunity", Nat. Rev. Rheumatol., (20100000), vol. 6, doi:10.1038/nrrheum.2009.237, pages 40 - 49, XP055541331 DOI: http://dx.doi.org/10.1038/nrrheum.2009.237 | - BENNETT, L. et al., "Interferon and granulopoiesis signatures in systemic lupus erythematosus blood", J. Exp. Med., (20030000), vol. 197, pages 711 - 723 | - PETERSON, K.S. et al., "Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli", J. Clin. Invest., (20040000), vol. 113, pages 1722 - 1733 | - BENGTSSON, A.A. et al., "Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies", Lupus, (20000000), vol. 9, pages 664 - 671 | - SANTIAGO-RABER, M.L. et al., "Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice", J. Exp. Med., (20030000), vol. 197, pages 777 - 788 | - DENG, Y. et al., "Genetic susceptibility to systemic lupus erythematosus in the genomic era", Nat. Rev. Rheumatol.,, (20100000), vol. 6, pages 683 - 692 | - SANDLING, J.K. et al., "A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE", Eur. J. Hum. Genet., (20110000), vol. 19, pages 479 - 484 | - BAVE, U. et al., "Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism", Arthritis Rheum., (20050000), vol. 52, pages 1185 - 1195 | - KIM, D. et al., "Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis", Arthritis Rheum., (20080000), vol. 58, pages 2163 - 2173 | - ISHIZAKI, M. et al., "Involvement of Tyrosine Kinase-2 in Both the IL-12/Thl and IL-23/Thl7 Axes In vivo", J. Immunol., (20110000), vol. 187, pages 181 - 189 | - PRCHAL-MURPHY, M. et al., "TYK2 kinase activity is required for functional type I interferon responses in vivo", PLoS One, (20120000), vol. 7, page e39141 | - MINEGISHI, Y. et al., "Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity", Immunity, (20060000), vol. 25, doi:10.1016/j.immuni.2006.09.009, pages 745 - 755, XP055573304 DOI: http://dx.doi.org/10.1016/j.immuni.2006.09.009 | - OYAMADA, A. et al., "Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis", J. Immunol., (20090000), vol. 183, pages 7539 - 7546 | - COUTURIER, N. et al., "Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility", Brain, (20110000), vol. 134, pages 693 - 703 | - ELLINGHAUS, D. et al., "Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci", Am. J. Hum. Genet., (20120000), vol. 90, pages 636 - 647 | - GRAHAM, D. et al., "Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families", Rheumatology (Oxford), (20070000), vol. 46, pages 927 - 930 | - EYRE, S. et al., "High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis", Nat. Genet., (20120000), vol. 44, pages 1336 - 1340 | - RAUTIO, J. et al., Nature Review Drug Discovery, (20180000), vol. 17, pages 559 - 587 | - MOSLIN, J. Med. Chem, (20190000), vol. 62, pages 8953 - 8972 |